Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects systemic synovial joints (Firestein, 2003) . In RA, proliferation of synovial cells and infiltration of activated immuno-inflammatory cells including T cells, macrophages and plasma cells (Firestein, 2003) leads to progressive destruction of cartilage and bone. Various cytokines, including interleukin-1β (IL-1β), tumor necrosis factor α (TNFα), IL-6, IL-8, IL-17 and macrophage colony stimulating factor, are present in the synovial fluid and tissue of RA patients (Okamoto, 2006) .
Synovial hyperplasia in RA is considered to be due to the impairment of apoptosis (Huber et al., 2006) . Most of the above mentioned pathophysiological features of RA can be explained by activation of a transcription factor nuclear factor kappa B (NF-κB) (Feldmann, 2001; Okamoto, 2005; Okamoto, 2006) , which is highly activated in the synovial lining cells of RA joint tissue (Sakurada et al., 1996; Huber et al., 2006) . NF-κB induces both TNFα and IL-1β gene expression while TNFα and IL-1β stimulate NF-κB signalling, forming a vicious cycle that can perpetuate and expand the inflammatory responses. Thus, blocking this cascade by inhibiting NF-κB signalling is considered feasible for the treatment of RA.
Interestingly, some of the drugs for RA were shown to block either the NF-κB-activation cascade or its action (Yang et al., 1995; Yamamoto and Gaynor, 2001; Okamoto, 5 JPET#158899 Moreland et al., 1997) . However, these drugs are expensive and have to be administered by injection and various adverse effects were reported, thus warranting necessity of effective small molecular compounds.
NF-κB is a hetero-or homodimer consisting of Rel family proteins, p65 (RelA), RelB, c-Rel, p50/p105 and p52/p100, and normally present in the cytoplasm in association with its inhibitor, IκB (Zabel and Baeuerle, 1990) . Stimulation by the proinflammatory cytokines such as TNFα and IL-1β results in the activation of IκB kinase (IKK) complex (Nakano et al., 1998) , which consists of three subunits, IKKα, IKKβ and IKKγ/NEMO. Activated IKK complex, mainly through the IKKβ activity (Mercurio et al., 1997; Zandi et al., 1997; Li et al., 1999b; Karin and Delhase, 2000) , phosphorylates IκBα leading to ubiquitination and degradation of IκB. NF-κB, then, translocates to nucleus and binds to the κB site of target genes. In this regard, IKKβ is a reasonable molecular target for blocking NF-κB signalling upon inflammatory stimuli.
NF-κB is highly activated not only in the synovial tissue of patients with RA, but also in some types of neoplasm such as multiple myeloma and adult T-cell leukaemia (ATL) (Mori et al., 1999; Sanda et al., 2005; Sanda et al., 2006) . In these cells, NF-κB is constitutively activated as evidenced by (1) the continuous phosphorylation of IκBα and p65 subunit of NF-κB, (2) activation of NF-κB DNA binding and (3) upregulation of various target genes that are responsible for inhibition of apoptosis. Moreover, a specific IKK inhibitor, ACHP (2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-piperidin-4-yl nicotinonitrile) (Murata et al., 2004) , could inhibit cell growth and induce apoptosis of multiple myeloma and ATL cells (Sanda et al., 2005; Sanda et al., 2006) by inhibiting the phosphorylation of IκBα and p65.
In this study, we examined the effects of a novel IKK inhibitor, CHPD (7-[2- over other kinases (Ziegelbauer et al., 2005) . In addition, CHPD showed good aqueous solubility and cell-permeability, thus demonstrating a very high oral bioavailability in mice and rats (Ziegelbauer et al., 2005) . However, effects of CHPD on the production of inflammatory cytokines have never been examined. Here we show that CHPD could effectively block NF-κB pathway in rheumatoid synovial fibroblasts (RSF) and inhibit the production of IL-6 and IL-8 from these cells upon induction of NF-κB by TNFα. Future perspective of this compound in the treatment of RA is discussed.
This article has not been copyedited and formatted. The final version may differ from this version. Fig. 1a . Human recombinant TNFα was purchased from Roche (Mannheim, Germany) and used at 1.0 ng/ml for NF-κB stimulation. Antibodies for IκBα (sc-371), p65 (sc-372) and α-tubulin (sc-8035) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA), while the antibody for phospho-IκBα (Ser32) (#9241L), JNK (#9252), phospho-JNK (Thr183/Tyr185) (#9251), ERK1/2 (#9102) and phosphor-ERK1/2 (Thr202/Tyr204) (#9191) was purchased from Cell Signaling Technology (Beverly, MA). Murine monoclonal TNFα antibody (MAB610) used in the neutralization assay (Fig. 1b) was commercially obtained (R&D Systems, Minneapolis, MN) and used at 10 μg/ml. Horseradish peroxidase-conjugated secondary antibodies were obtained from Amersham Biosciences (Little Chalfont, United Kingdom).
Patients:
RSF cultures were isolated from fresh synovial tissue biopsy samples from six RA patients at total knee arthroplasty or arthroscopic synovectomy as previously reported (Sakurada et al., 1996; Yoshida et al., 1999a; Yoshida et al., 1999b) . Diagnosis of RA was made according to the clinical criteria of the American College of Rheumatology (Arnett et al., 1988) . These RA patients included five females and one male, from 37 to 63years old, and all patients had active RA at various clinical stages and classes. The mean disease This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on January 6, 2010 as DOI: 10.1124/jpet.109.158899 at ASPET Journals on November 13, 2017 jpet.aspetjournals.org Downloaded from JPET#158899 duration was 7.7 ± 6.7 year with a range of 1.4-18.0 years. Clinical characteristics of each donor are shown in Table1. None of the patients had been treated with any biologic agents such as Infliximab and Etanercept. Informed consents were obtained from each patient in conformity with the requirements of the ethics committee of the Nagoya City University Graduate School of Medical Sciences.
Cell culture:
RSF cultures were performed as previously reported (Sakurada et al., 1996; Yoshida et al., 1999a; Yoshida et al., 1999b) . Briefly, fresh synovial tissue biopsy samples were minced into small pieces and treated with 1 mg/ml collagenase/dispase (Roche Diagnostics GmbH, Mannheim, Germany) for 10-20 min at 37 °C. The cells were cultured in F-12 (HAM) (Invitrogen Co.) supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml of penicillin, 100 μg/ml of streptomycin and 0.5 mM mercaptoethanol. The culture medium was changed every 3-5 days and nonadherent lymphoid cells were removed during the initial passages. All the experiments were conducted using synoviocyte cultures during the third to eighth passages. To characterize the cytological phenotype, the cells were stained with mouse monoclonal antibodies against human HLA-DR, von Willebrand factor, desmin, smooth muscle actin, CD1a, CD68 and 5B5 (DAKO, Glostrup, Denmark). Only 5B5 was positive for RSF, indicating their fibroblast-like phenotype, consistent with our previous findings (Sakurada et al., 1996; Yoshida et al., 1999a; Yoshida et al., 1999b) . There was some heterogeneity in cell growth property of each RSF preparation, however, there was no quantitative difference that warrant aggressive nature of synovial cells. Human embryonic kidney 293 cells were grown at 37 °C in Dulbecco's modified Eagle's medium (Sigma) with 10% heat-inactivated fetal bovine serum, 100 U/ml of penicillin and 100 μg/ml of streptomycin.
This article has not been copyedited and formatted. The final version may differ from this version. The cytokine concentrations were determined using cytokine-specific ELISA kits for IL-6 and IL-8 (Quantikine ELISA kits; R&D Systems) in RSF and 293 cells culture supernatant with experimental procedures recommended by the manufacturer. Triplicates were used for each test condition in the three independent cultures.
Cell proliferation assay:
In order to examine the cytotoxicity of CHPD, the cell proliferation of RSF upon treatment with CHPD at various concentrations was determined using WST-1 (Roche Diagnostics) according to the manufacturer's protocol. In brief, RSF cultures were incubated with CHPD in a 96 well plate for 24 h, incubated further for 4 h in the presence of WST-1, and the dissolved formazan was measured at 450 nm by spectrophotometry.
RT-PCR:
To measure mRNA expression of various genes, 2.0 x 10 5 RSF cells were cultured at 37 °C in CO 2 incubator, washed once with PBS, homogenized with QIAshredder (Qiagen, Alameda, CA), and total RNA was purified using RNeasy (Qiagen) according to (http://rsbweb.nih.gov/ij/download.html).
Immunoblot analyses:
For detection and analyses of various proteins, RSF cells were maintained with or without CHPD at 37 °C. These cells were washed once with cold phosphate-buffered saline (PBS) and resuspended in 50 μl of lysis buffer containing 20 mM HEPES-NaOH (pH7.9), 150 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , 5 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 0.2% Triton X-100 and protease inhibitors cocktail (Roche Diagnostics). After 15 min of incubation on ice, the samples were centrifuged at 15,000 rpm for 10 min and the supernatant was collected as "whole cell extract". Protein concentration was measured using Tween 20) containing 5% nonfat milk for 1 h at room temperature, and incubated with TBS-T containing 5% nonfat milk and 1:1,000 diluted specific antibodies overnight at 4 °C. After incubation, the membranes were rinsed three times with TBS-T and further incubated with horseradish peroxidase-conjugated secondary antibodies in TBS-T with 5% nonfat milk at room temperature for 1 h. Each protein was detected by chemi-luminescence using SuperSignal (Pierce, Rockford, IL).
JPET#158899

Transfection and luciferase assay:
The 293 cells (1.0 x 10 5 /well) were transfected with reporter plasmids using FUGENE 6 transfection reagent (Roche Applied Science) according to the manufacturer's instructions.
For each transfection, 0.03 μg of 4κB-luc, where luciferase gene expression is under the control of NF-κB, and 0.01 μg of the internal control plasmid, pRL-TK, expressing Renilla luciferase under the control of TK promoter, were used (Yang et al., 1999) . Twenty-four hours after transfection, the cells were treated with CHPD for 30 min and stimulated with TNFα (1.0 ng/ml) for 24 h. The transfected cells were then harvested, and the extracts were subjected to luciferase assay using the Luciferase Assay System (Promega). The luciferase activity was normalized with Renilla luciferase activity as an internal control to assess the transfection efficiency.
ChIP assays:
Chromatin immunoprecipitation (ChIP) assays were performed using ChIP assay kits relative amount of il-8 promoter DNA bound to p65 was quantified by densitometric scanner using Image J software that was downloadable from (http://rsbweb.nih.gov/ij/download.html).
Statistical analysis:
The statistical significances of difference were evaluated by the Steel-Dwass's test with p<0.05 considered statistically significant.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
CHPD inhibited the spontaneous IL-6 production from RSF -
To investigate the inhibitory effect of CHPD on the production of IL-6 upon stimulation of RSF with TNFα (1.0 ng/ml), involving NF-κB activation, cytokine concentration was measured in the cell culture supernatant 24 h after stimulation. As shown in Fig. 1b , the extent of spontaneous production of IL-6 from RSF was much higher than that from 293 cells (data not shown), a human epithelial cell line and downregulated by CHPD but not by neutralizing antibody to TNFα. The extent of inhibition of the spontaneous production of IL-6 by 1.0 μM CHPD was 41%. In addition, a neutralizing antibody against IL-1β did not change the levels of IL-6 spontaneously produced from RSF (data not shown). The representative data with RSF1 are shown in Fig. 1b and similar results were observed with other RSF cultures (data not shown). These data suggest that this spontaneous production of cytokines might be due to other factors involving IKKβ. In addition, we did not detect detectable levels of TNFα or IL-1β production in this study (data not shown) which we have reported previously (Sakurada et al., 1996) .
CHPD inhibited the IL-6 and IL-8 production induced by TNFα from RSF -
In Table 2 , we have measured the levels of IL-6 and IL-8 production in the culture supernatant of RSF cultures obtained from 6 individual patients with RA. As shown, the extent of augmentation of production of inflammatory cytokines after 24 h
TNFα stimulation were 1.8-7.1 fold and 19.6-35.7 fold for IL-6 and IL-8, respectively.
The concentrations of spontaneous production of IL-6 without TNFα stimulation in the absence and the presence of 1 μM CHPD were 2.3 ± 0.9 and 1.8 ± 0.6 ng/ml, respectively. Similarly, we measured the extents of inhibition of production of these cytokines upon TNFα stimulation by CHPD (as indicated by IC50 values). We noted a slight heterogeneity in the responsiveness to the TNFα treatment and CHPD in these synovial cell cultures. Interestingly, when RSF cultures from 6 RA patients were pretreated with CHPD for 1 h before TNFα treatment, the extents of IL-6 and IL-8 induction were significantly reduced by CHPD in a concentration-dependent manner (Fig.2a, b) . Although there was heterogeneity in the responsiveness to CHPD, a concentration-dependent suppression of cytokine production by CHPD was noted.
IL-8 appeared to be preferentially inhibited by CHPD. The extents of inhibition by 1.0 μM CHPD of the TNFα-induced production of IL-6 or IL-8 were 55% (Fig.2a) and 90% (Fig.2b ) in average for IL-6 and IL-8, respectively. CHPD at these concentrations did not show significant cytotoxicity (Fig. 2c) . These results indicate that CHPD suppressed the IL-6 and IL-8 cytokine levels that were induced by TNFα without significant inhibition of cell proliferation or cytotoxicity.
CHPD inhibited TNFα-induced il-6 and il-8 mRNA expression -
To further examine whether CHPD suppresses the TNFα-induced gene expression of il-6 and il-8, we semi-quantitatively detected the mRNA levels of il-6
and il-8 using RT-PCR. As demonstrated in Fig. 3a , the il-6 and il-8 mRNA expression levels in RSF were increased as early as 1 h until 16 to 24 h after TNFα stimulation (at 1.0 ng/ml) and then gradually decreased. When RSF was pretreated with 1.0 μM CHPD for 1 h before the treatment with TNFα, the extent of induction of il-6 and il-8 mRNA were significantly reduced by CHPD (Fig. 3b) . These results indicate that CHPD could inhibit il-6 and il-8 mRNA synthesis that were induced by TNFα. In addition to il-6 and il-8, gene expressions of vcam-1 (Iademarco et al., 1992) and mmp-3 (Borghaei et al., 2004) , also under the control of NF-κB, were induced by TNFα and effectively inhibited by CHPD.
CHPD inhibited TNFα-induced IκBα phosphorylation and degradation-
TNFα stimulation activates IKK complex and the activated IKKs induce IκBα phosphorylation, leading to ubiquitination and subsequent degradation of IκBα by the 26S proteasome (Okamoto, 2006) . We then examined the inhibitory effect of CHPD on TNFα-induced IκBα phosphorylation and degradation by immunoblot analysis.
As shown in Fig. 4a , TNFα stimulation caused IκBα phosphorylation ("P-IκBα"), which was observed at 5 min after stimulation of RSF. However, treatment with CHPD reduced IκBα phosphorylation in a concentration-dependent manner (Fig. 4b ).
CHPD at 1.0 μM appeared to prevent the phosphorylation of IκBα in all the RSF cultures tested (data not shown). We then proceeded to examine whether CHPD could block IκBα degradation as well. As also shown in Fig. 4 , the IκBα protein committed nearly complete degradation in RSFs 15 min after TNFα stimulation and blocked by 1.0 μM CHPD. In contrast, α-tubulin levels were unchanged, indicating equal loading of proteins in the gel. Furthermore, although MAPK family members including JNK and ERK were reported to be activated by TNFα stimulation (Firestein, 2003) , CHPD failed to inhibit these kinases (Fig. 4c, d ). In addition, although there are two JNK molecular species, p54 and p46, we could detect only p46 protein. 
CHPD inhibited gene expression driven by TNFα and analysis with chromatin immunoprecipitation (ChIP) assay-
We then examined the effect of CHPD on NF-κB dependent gene expression using luciferase assay with the 4xκB-luc reporter plasmid, where luc gene expression depends on NF-κB (Yang et al., 1999) . Since RSF cultures were hardly susceptible to gene transfection even using various modifications of lipofection, a human cell line derived from embryonic kidney, 293 cells, that is more susceptible for gene transfection, were utilized instead. As shown in Fig. 5a , TNFα stimulated expression of NF-κB dependent gene such as 4xκB-luc by 17.0 ± 3.8 fold, which was similarly observed as in the case of TNFα-induced IL6/IL-8 production (Fig. 2 , Table 2 ).
When cells were pretreated with CHPD, however, the gene expression was inhibited in a concentration-dependent manner (Fig. 5a ). Approximately 80% of this activity was inhibited at 2.0 μM of CHPD.
To further confirm the nuclear translocation and promoter binding of NF-κB, we have adopted ChIP assay and examined the inhibitory effect of CHPD on the 
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Discussion
The intervention therapy using blocker of TNFα, IL-1β and IL-6 has been developed and demonstrated remarkable therapeutic efficacies (Elliott et al., 1993; Moreland et al., 1997; Bresnihan et al., 1998; Nishimoto et al., 2004) . These findings indicate that these proinflammatory cytokines, which eventually lead to activation of NF-κB, play crucial roles in the pathogenesis of RA among other signalling cascades (Firestein, 2003; Okamoto, 2006) . However, these cytokine blockers currently used are considered "biologic agents" requiring intradermal or intravenous injections, inducing allergic reactions as well as adverse effects and consuming substantial medical resources. Thus, development of small molecular weight chemical compounds which share a similar molecular target is desperately needed.
The biological cascade involving NF-κB forms a positive feedback loop, or "vicious cycle", that can perpetuate by itself and expand the inflammatory responses to other joints and tissues (Okamoto, 2006) . Thus, inhibiting NF-κB signalling by blocking this cycle is considered to be a feasible treatment strategy of RA (Feldmann, 2001; Okamoto, 2006) . (DHMEQ) appears to inhibit the nuclear translocation of NF-κB (Wakamatsu et al., 2005) and PS341 (Bortezomib) was identified to inhibit proteasome (Adams et al., 1999) . Among these target molecules, however, IKK complex appears to be specific for NF-κB activation and is the converging molecule of a number of distinct NF-κB-activating agents such as TNFα, IL-1β, B-cell activating factor, lymphotoxin β, CD40
and Toll-like receptor signalling (Okamoto, 2006) . , 2005) . In addition, CHPD did not exert any inhibitory effect on JNK and ERK in RSF (Fig. 4d) and AP-1 in normal human lung fibroblast MRC5 (Ziegelbauer et al., 2005) . These characteristics indicate that CHPD is one of the feasible candidates for therapeutic IKKβ inhibitor, although further improvements are needed as therapeutic compounds. Since the inhibitory effects of CHPD were observed with synovial cell cultures that showed relatively rapid cell growth ex vivo, further studies in this area are warranted.
As previously discussed, IKKβ represents the major effector kinase in the canonical pathway of NF-κB activation, IKKα on the other hand is primarily involved in the non-canonical pathway (Okamoto, 2006) . Although IKKβ knockout mice exhibited early embryonic death because of the massive apoptosis in liver (Li et al., 1999a) , gene knockout of IKKα showed only impairment in skin and digit abnormality such as syndactyly (Hu et al., 1999) . Moreover, recent experimental evidences (Enzler et al., 2006; Okamoto, 2006) have indicated the crucial importance of IKKα in autoimmunity. However, considering the crosstalk between the canonical and non-canonical pathways, such as phosphorylation of p65 at Ser536 and subsequent induction of the transcriptional activity of NF-κB (Jiang et al., 2003a; Jiang et al., 2003b) , application of IKKβ inhibitor for the treatment of rheumatic diseases should be considered.
We noticed the production of inflammatory cytokines such as IL-6 from rheumatoid synovial cell cultures without stimulation with TNFα (Fig. 1b) . Since neutralizing antibodies to TNFα and IL-1β did not but CHPD did block the production of these cytokines, other factors that can stimulate the NF-κB cascade involving IKKβ, such as oxidative or environment stress and irradiation, are considered to be involved in such background activity. In addition, we could not find by Miyazawa et al. (Miyazawa et al., 1998) where constitutive IL-6 production was observed without any stimulation in rheumatoid synoviocytes from 11 RA patients whereas no such background production of inflammatory cytokines was detected in dermal fibroblasts and synoviocytes from osteoarthritis.
In conclusion, NF-κB activation in synovial cells and production of -6, il-8, mmp-3, vcam- 1 genes induced by 1.0 ng/ml TNFα. RSF cultures were stimulated by TNFα for 16 h with or without pre-treatment of 1.0 μM CHPD that was added 1 h before.
The representative data with two independent RSF cultures are shown. 
